Syfovre vs Izervay
A side-by-side look at two eye health medications advertised on TV. Informational only — not medical advice.
| US Syfovre | US Izervay | |
|---|---|---|
| Generic name | pegcetacoplan | avacincaptad pegol |
| Drug class | Complement C3 Inhibitor | Complement C5 Inhibitor |
| Treats | Geographic atrophy (advanced dry AMD) | Geographic atrophy (advanced dry AMD) |
| Category | Eye Health | Eye Health |
| Manufacturer | Apellis Pharmaceuticals | Astellas Pharma |
| Year approved | 2023 | 2023 |
| FDA warning | Moderate warnings | Moderate warnings |
| Est. TV ad spend | — | — |
| Common side effects | Eye discomfort, Floaters, Bleeding in the eye, Increased eye pressure | Bleeding in the eye, Increased eye pressure, Floaters, Risk of eye infection |
Frequently asked questions
Is Syfovre or Izervay better?
Neither is universally "better." Syfovre (pegcetacoplan) and Izervay (avacincaptad pegol) are both used for eye health, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Syfovre and Izervay?
Syfovre is a Complement C3 Inhibitor made by Apellis Pharmaceuticals, while Izervay is a Complement C5 Inhibitor made by Astellas Pharma. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Syfovre has the larger estimated TV advertising budget of the two.